Company Performance Metrics
Robert Coates: Executive Chairman
Past Role: Canaccord Genuity Group, Co-head of investment banking and Head of healthcare
Memgen specializes in developing cancer immunotherapies to harness the power of the immune system. to potentially cure cancer and protect people from COVID-19 and other diseases. The company’s pipeline products all utilize its proprietary CD40L transgene, MEM40, which has already been tested in clinical trials and has demonstrated the ability to
elicit powerful, antigen-specific immune responses.
The company’s cancer immunotherapy, MEM-288, was developed in collaboration with Moffitt Cancer Center. It is an oncolytic virus engineered to selectively target cancer cells and to supercharge the immune system through the expression of two unique and powerful immune modulators: MEM40 and the powerful cytokine interferon beta. MEM-288 generates a strong systemic anti-tumor immune response following intra-tumoral vaccination in multiple tumors. Memgen expects to begin clinical testing with MEM-288 in advanced cancers in the current year.
Memgen's COVID-19 vaccine, MemVax, is an adjuvant designed to be used in combination with other COVID-19 vaccines to generate a strong, durable immune response. MemVax is a specific immune stimulant that can work with COVID-19 antigens across a range of delivery approaches. Memgen has over 100,000 doses of MemVax ready to go into clinical trials and an active file with the US FDA. Memgen plans to soon begin clinical trials of MemVax in collaboration with other companies developing complementary COVID-19 vaccines.
